ARWR ARROWHEAD PHARMACEUTICALS, INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$74.52

Period return

+4.93 (+7.08%)

Volume

1.6M

2026-07-21O $72.81 H $74.68 L $72.62 C $74.52MA5 $72.73MA20 $78.68MA60 $76.73MA120 $70.05

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 14.LowHOLD2 months ago
Bernstein: Market Perform
US analyst rating / recommendation change.
2026. 05. 09.LowBUY2 months ago
RBC Capital: Outperform
US analyst rating / recommendation change.
2026. 05. 01.MediumBUY3 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 04. 21.MediumBUY3 months ago
Morgan Stanley: Overweight
US analyst rating / recommendation change.
2026. 03. 26.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 02. 10.LowBUY5 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 01. 22.LowBUY6 months ago
B. Riley Securities: Buy
US analyst rating / recommendation change.
2026. 01. 22.LowBUY6 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 01. 14.LowBUY6 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $88.17 · 12 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Sector: Healthcare
Industry: Biotechnology

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$-1.2	—	—	$46.68M	—	Scheduled
FY2026 Q2	2025. 03. 31.	Time TBD	—	$1.52	—	—	$545.21M	Reported
FY2026 Q1	2024. 12. 31.	Time TBD	—	$-1.39	—	—	$2.5M	Reported
FY2025 Q3	2024. 06. 30.	Time TBD	—	$-3.63	—	—	$3.55M	Reported

ARROWHEAD PHARMACEUTICALS, INC.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 14.	Bernstein	—	Maintain	Market Perform → Market Perform	—	Bernstein: Market Perform
2026. 05. 09.	RBC Capital	—	Maintain	Outperform → Outperform	—	RBC Capital: Outperform
2026. 05. 01.	JP Morgan	—	Initiate coverage	— → Overweight	—	JP Morgan: Overweight
2026. 04. 21.	Morgan Stanley	—	Upgrade	Equal-Weight → Overweight	—	Morgan Stanley: Equal-Weight → Overweight
2026. 03. 26.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 02. 10.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy